KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Retained Earnings (2016 - 2025)

Historic Retained Earnings for Travere Therapeutics (TVTX) over the last 17 years, with Q3 2025 value amounting to -$1.5 billion.

  • Travere Therapeutics' Retained Earnings fell 638.39% to -$1.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.5 billion, marking a year-over-year decrease of 638.39%. This contributed to the annual value of -$1.4 billion for FY2024, which is 2856.6% down from last year.
  • Travere Therapeutics' Retained Earnings amounted to -$1.5 billion in Q3 2025, which was down 638.39% from -$1.5 billion recorded in Q2 2025.
  • Over the past 5 years, Travere Therapeutics' Retained Earnings peaked at -$639.7 million during Q1 2021, and registered a low of -$1.5 billion during Q2 2025.
  • For the 5-year period, Travere Therapeutics' Retained Earnings averaged around -$1.1 billion, with its median value being -$1.1 billion (2023).
  • As far as peak fluctuations go, Travere Therapeutics' Retained Earnings plummeted by 5391.88% in 2021, and later tumbled by 638.39% in 2025.
  • Travere Therapeutics' Retained Earnings (Quarter) stood at -$766.0 million in 2021, then crashed by 32.41% to -$1.0 billion in 2022, then dropped by 10.98% to -$1.1 billion in 2023, then decreased by 28.57% to -$1.4 billion in 2024, then fell by 1.95% to -$1.5 billion in 2025.
  • Its last three reported values are -$1.5 billion in Q3 2025, -$1.5 billion for Q2 2025, and -$1.5 billion during Q1 2025.